News

Over the past seven months, Mersana and Takeda have been conducting pre-clinical, proof-of-concept studies for several Fleximer-ADCs against an undisclosed oncology target under a research license to Mersana’s

XTEN is Amunix’s proprietary protein-based polymer that mimics the biophysical properties of PEG and is used to extend the half-life of genetically fused therapeutic proteins and peptides. "We

Keytruda is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. The breakthrough status for Keytruda is to treat these patients

As part of the acquisition, MPI will acquire the Jasper Clinic, a 50-bed clinical trial unit that offers a wide range of early-stage study services, including pharmacokinetic and

While BDSI plans to pursue an indication for the maintenance treatment of opioid dependence, the company has also secured the rights and plans to develop a product for

EPP is characterized by an extreme risk of severe burns of the skin resulting in intolerable pain, swelling, scarring and a state of distress. The company said that

The latest acquisition will be combined with CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL. The transaction requires regulatory approvals and is expected to be completed in the second

Targin is a fixed combination of opioid agonist oxycodone and opioid antagonist naloxone in prolonged-release oral tablets. The drug, which is currently licensed for the treatment of RLS

The drug secured CHMP positive opinion for treatment of mCRPC patients who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy in whom chemotherapy is not yet